The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...

Seiji Wakao, JPMorgan, queried the feasibility of achieving ¥1 trillion in oncology revenue amid Datroway’s setbacks. Ogawa stated that ENHERTU’s performance could potentially fill the gap, with a ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

The first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant Datroway (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy ...

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...